ABBV Stock Price Today (October 2026) — AbbVie Inc. Analysis & Key Metrics 2026-10-08
AbbVie Inc. (ABBV) is trading at $272.42, up 0.39% today (as of October 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $278.86 (2.4% upside).
- Volatility is low (10.36% annualized), implying relatively contained price movements for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (10.20% YoY) alongside competitive pressures in the Drug Manufacturers - General space.
ABBV Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
AbbVie Inc. - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $545.71B
P/E Ratio
Forward P/E: 15.75
Revenue Growth
Year over Year
Analyst Target
+2.4% upside potential
Key Investor Questions About ABBV
What investors need to know before buying
Based on current market data, ABBV presents a overbought technical setup with mixed signals fundamentals.
- Technicals say: Overbought (RSI 71.82)
- Fundamentals say: Mixed signals (nuanced financial profile)
ABBV's growth trajectory depends on its ability to expand within the Drug Manufacturers - General sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - General operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for ABBV investors include debt exposure and competitive dynamics in the Drug Manufacturers - General industry.
- $70.88B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - General.
52-Week Trading Range
Over the past year, ABBV stock traded between $190.75 and $269.39 and currently trades near the high end of that range. Big swings are less likely unless a major catalyst emerges.
Volatility & Risk Profile
With 10.36% annualized volatility and β=0.09, the stock exhibits low sensitivity to market moves—making ABBV suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional ownership with low short interest suggests steadier hands and low immediate risk.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie bets on pipeline diversification amid patent cliffs, while J&J's higher profitability masks litigation risks, a choice between growth ambition and defensive stability.
AbbVie vs. Pfizer: Which Healthcare Stock Makes Your Portfolio Healthier in 2026?
AbbVie pivots toward newer immunology drugs while Pfizer leans on acquisitions to offset pandemic decline, but their financial profiles and valuations tell starkly different stories.
ABBV vs. JNJ: One of These Dividend Aristocrats Will Crush the Other Over the Next Decade
AbbVie and Johnson and Johnson both trade near 52-week highs and carry decades of dividend raises, but one faces a patent cliff and a leveraged balance sheet that could force retirees to rethink their income strategy completely.
ADARx Pharmaceuticals raises $446 million in upsized IPO
The San Diego RNA drug developer sold 26.3 million shares at $17 apiece, with AbbVie investing up to $100 million in a concurrent private placement
AbbVie vs. Novo Nordisk: Which Drug Giant Stock Is a Better Buy in 2026?
Novo Nordisk trades at a steep discount on earnings and sales, while AbbVie grapples with patent cliffs and pricing pressure, but profitability tells a different story.
AbbVie (ABBV) Won EU Approval For RINVOQ In Pediatric Arthritis
AbbVie (NYSE:ABBV) received European Commission approval for RINVOQ in polyarticular juvenile idiopathic arthritis for patients as young as two. Allergan Aesthetics launched AA Signature SKIN360 in the U.S., offering a multimodal digital platform for medical aesthetics consultations. AbbVie entered AI-focused collaborations with Iambic and the AISB Bind project to use advanced models in drug discovery and molecular binding prediction. The RINVOQ pediatric extension, AA Signature SKIN360...
AbbVie (ABBV) Wins EU Approval for Rinvoq in Children. Why a Small Indication Still Matters
AbbVie Inc. (NYSE:ABBV) said on September 22 that the European Commission has approved Rinvoq for children aged two and older with active polyarticular juvenile idiopathic arthritis. The approval covers patients who did not respond to, or could not tolerate, standard disease-modifying drugs. It is the eleventh indication Rinvoq holds in Europe. The Commission also cleared […]
AbbVie's Rinvoq Wins EU Approval in Juvenile Idiopathic Arthritis
ABBV's Rinvoq secures EU approval for pJIA in children, expanding ABBV's reach as clinical data show sustained improvements in disease activity.
An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide
Alkermes’ results heightened anticipation for a coming readout in 2027. Elsewhere, AbbVie leaned into AI drug discovery and the FDA expanded use of Eli Lilly’s breast cancer pill.
Reflecting On Therapeutics Stocks’ Q2 Earnings: AbbVie (NYSE:ABBV)
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at AbbVie (NYSE:ABBV) and its peers.
Explore More Analysis for ABBV
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Oct 30, 2026 (before the open, usually)
Frequently Asked Questions
Common investor questions about AbbVie Inc.
AbbVie Inc. (ABBV) is currently trading at $272.42. The RSI (14-day) is at 71.8, indicating overbought territory (potentially overheated). Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $278.86 implies 2.4% upside from current levels. Volatility is low at 10.4% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for AbbVie Inc. (ABBV): The trailing P/E ratio is 73.74, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 15.75, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 0.42, below 1.0, which generally indicates the stock is undervalued relative to its growth rate. Price-to-Sales is 7.18. Valuation should be compared to Drug Manufacturers - General industry peers for context, as different sectors trade at different multiples.
Based on 28 analysts covering ABBV, the consensus price target is $278.86. This represents a 2.4% upside from the current price of $272.42. The range spans from a low target of $200.00 to a high target of $328.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, AbbVie Inc. (ABBV) pays a dividend with a current yield of approximately 2.54%. The annualized dividend rate is $6.83 per share. The payout ratio is 190.4%, which exceeds 100%—this means the company is paying out more than it earns, which may not be sustainable long-term. The most recent ex-dividend date was Oct 15, 2026.
Key risks for AbbVie Inc. (ABBV) investors include: 1. Unsustainable dividend payout ratio (190%) could lead to a dividend cut. 2. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 3. Drug Manufacturers - General sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is AbbVie Inc.'s (ABBV) current debt and financial health profile: Total debt stands at $70.88B. The current ratio is 0.81, which is below 1.0 and may indicate short-term liquidity concerns. The quick ratio is 0.49. The company holds $6.57B in cash and equivalents. Free cash flow is positive at $16.87B, providing a cushion for debt servicing and shareholder returns.